Skip to main content
SpringerLink
Log in

Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren’s syndrome

  • Original Article
  • Published:
Modern Rheumatology

Abstract

In Sjögren’s syndrome (SS), oral dryness (xerostomia) is frequently the most bothersome symptom. An H2 histamine receptor antagonist is often administered to SS patients to treat associated superficial gastritis. The aim of the present study was to assess the ability of nizatidine, an H2 receptor antagonist, to also relieve xerostomia in patients with primary SS. Twenty-seven patients with primary SS were randomly assigned to receive nizatidine (n = 14, 300 mg a day) or another H2 blocker, famotidine (n = 13, 40 mg a day; control), were followed for eight weeks, and were asked for both subjective and objective assessments of oral dryness using a visual analog scale (VAS; 1–100 mm) and the Saxon’s test, respectively. Patients receiving oral nizatidine, but not famotidine, obtained significant objective relief from their xerostomia (Saxon’s test; baseline, 0.57 g/2 min; after eight weeks, 0.90 g/2 min, P < 0.05). VAS scores indicated that nizatidine also provides mild improvement (20% improvement over baseline) of xerostomia-related clinical conditions, including mouth dryness and difficulty in chewing, tasting and swallowing food. Both drugs were generally well tolerated, without adverse effects. The present preliminary study suggests that nizatidine may represent a new option for the treatment of xerostomia in SS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

SS:

Sjögren’s syndrome

VAS:

Visual analog scale

References

  1. Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33:95–106.

    Article  PubMed  Google Scholar 

  2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164:1275–84.

    Article  PubMed  Google Scholar 

  3. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL 3rd, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159:174–81.

    Article  PubMed  CAS  Google Scholar 

  4. Wall GC, Magarity ML, Jundt JW. Pharmacotherapy of xerostomia in primary Sjogren’s syndrome. Pharmacotherapy. 2002;22:621–9.

    Article  PubMed  CAS  Google Scholar 

  5. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162:1293–300.

    Article  PubMed  CAS  Google Scholar 

  6. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748–54.

    Article  PubMed  CAS  Google Scholar 

  7. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64:347–54.

    Article  PubMed  CAS  Google Scholar 

  8. Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, et al. (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol. 1998;78:373–80.

    Article  PubMed  CAS  Google Scholar 

  9. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren’s syndrome. Clin Immunol. 2001;101:249–63.

    Article  PubMed  CAS  Google Scholar 

  10. Neya T, Itano N, Mizutani M, Yamasato T, Takaki M, Nakayama S. The effect of cisapride on neural 5-HT receptors in guinea-pig isolated ileum. Eur J Pharmacol. 1984;106:221–2.

    Article  PubMed  CAS  Google Scholar 

  11. Taniyama K, Nakayama S, Takeda K, Matsuyama S, Shirakawa J, Sano I, et al. Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J Pharmacol Exp Ther. 1991;258:1098–104.

    PubMed  CAS  Google Scholar 

  12. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993;329:390–5.

    Article  PubMed  CAS  Google Scholar 

  13. Kounenis G, Voutsas D, Koutsoviti-Papadopoulou M, Elezoglou V. Inhibition of acetylcholinesterase by the H2-receptor antagonist nizatidine. J Pharmacobiodyn. 1988;11:767–71.

    PubMed  CAS  Google Scholar 

  14. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, et al. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993;264:152–7.

    PubMed  CAS  Google Scholar 

  15. Adachi K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther. 2002;16:297–301.

    Article  PubMed  CAS  Google Scholar 

  16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis. 2002;61:554–8.

    Article  PubMed  CAS  Google Scholar 

  17. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128–32.

    Article  PubMed  CAS  Google Scholar 

  18. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol. 2000;12:391–8.

    Article  PubMed  CAS  Google Scholar 

  19. Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers. Curr Opin Rheumatol. 2003;15:563–70.

    Article  PubMed  Google Scholar 

  20. Sheikh SH, Shaw-Stiffel TA. The gastrointestinal manifestations of Sjogren’s syndrome. Am J Gastroenterol. 1995;90:9–14.

    PubMed  CAS  Google Scholar 

  21. Ostuni PA, Germana B, Di Mario F, Rugge M, Plebani M, De Zambiasi P, et al. Gastric involvement in primary Sjogren’s syndrome. Clin Exp Rheumatol. 1993;11:21–5.

    PubMed  CAS  Google Scholar 

  22. ter Borg EJ, Haanen HC, Haas FJ, Bistervels JH, Huisman FW, Kerckhaert JA, et al. Treatment of primary Sjogren’s syndrome with d-penicillamine: a pilot study. Neth J Med. 2002;60:402–6.

    PubMed  CAS  Google Scholar 

  23. Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Cyclosporin A (CyA) in primary Sjogren’s syndrome: a double blind study. Ann Rheum Dis. 1986;45:732–5.

    Article  PubMed  CAS  Google Scholar 

  24. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren’s syndrome. Clin Exp Rheumatol. 1996;14:555–8.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors have any conflicts of interest in connection with this work.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

    Tsuyoshi Kasama, Fumitaka Shiozawa, Takeo Isozaki, Mizuho Matsunawa, Kuninobu Wakabayashi, Tsuyoshi Odai, Nobuyuki Yajima, Yusuke Miwa, Masao Negishi & Hirotsugu Ide

Authors
  1. Tsuyoshi Kasama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumitaka Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Isozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mizuho Matsunawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kuninobu Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsuyoshi Odai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuke Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masao Negishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hirotsugu Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsuyoshi Kasama.

About this article

Cite this article

Kasama, T., Shiozawa, F., Isozaki, T. et al. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren’s syndrome. Mod Rheumatol 18, 455–459 (2008). https://doi.org/10.1007/s10165-008-0078-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-008-0078-4

Keywords

Search

Navigation